Do analysts recommend GMTX or EXEL?

Exelixis has a consensus price target of $49.79, indicating a potential downside of 1.88%. Given Exelixis' stronger consensus rating and higher probable upside, analysts plainly believe Exelixis is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Exelixis 2 Sell rating(s) 10 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.32

Do analysts recommend ARWR or GMTX?

Arrowhead Pharmaceuticals presently has a consensus target price of $97.33, indicating a potential upside of 14.28%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Arrowhead Pharmaceuticals is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arrowhead Pharmaceuticals 1 Sell rating(s) 3 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.62 Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate GMTX or MDGL?

Madrigal Pharmaceuticals has a consensus target price of $689.93, indicating a potential upside of 37.43%. Given Madrigal Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Madrigal Pharmaceuticals is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Madrigal Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 2.78

Do analysts rate GMTX or SMMT?

Summit Therapeutics has a consensus price target of $24.25, indicating a potential upside of 84.18%. Given Summit Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Summit Therapeutics is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Summit Therapeutics 2 Sell rating(s) 7 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.38

Which has better valuation & earnings, GMTX or SMMT?

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gemini Therapeutics N/A N/A -$71.87M -$1.00 N/A Summit Therapeutics N/A N/A -$1.08B -$1.12 N/A

Is GMTX or SMMT more profitable?

Gemini Therapeutics' return on equity of -38.78% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Gemini Therapeutics N/A -38.78% -35.88% Summit Therapeutics N/A -168.94% -141.92%

Gemini Therapeutics (GMTX) Competitors

$80.01 -0.58 (-0.72%)

As of 08/13/2026

Compare

GMTX vs. BMRN, EXEL, ARWR, MDGL, and SMMT

Should you buy Gemini Therapeutics stock or one of its competitors? Gemini Therapeutics's main competitors and comparable companies include BioMarin Pharmaceutical (BMRN), Exelixis (EXEL), Arrowhead Pharmaceuticals (ARWR), Madrigal Pharmaceuticals (MDGL), and Summit Therapeutics (SMMT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Gemini Therapeutics compare to BioMarin Pharmaceutical?

BioMarin Pharmaceutical (NASDAQ:BMRN) and Gemini Therapeutics (NASDAQ:GMTX) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends, earnings and media sentiment.

98.7% of BioMarin Pharmaceutical shares are owned by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are owned by institutional investors. 0.7% of BioMarin Pharmaceutical shares are owned by insiders. Comparatively, 12.9% of Gemini Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

BioMarin Pharmaceutical has a net margin of 2.14% compared to Gemini Therapeutics' net margin of 0.00%. BioMarin Pharmaceutical's return on equity of 5.32% beat Gemini Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioMarin Pharmaceutical	2.14%	5.32%	3.69%
Gemini Therapeutics	N/A	-38.78%	-35.88%

BioMarin Pharmaceutical currently has a consensus price target of $88.00, suggesting a potential upside of 30.70%. Given BioMarin Pharmaceutical's stronger consensus rating and higher probable upside, research analysts clearly believe BioMarin Pharmaceutical is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioMarin Pharmaceutical	1 Sell rating(s)	6 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.70
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

BioMarin Pharmaceutical has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioMarin Pharmaceutical	$3.22B	4.05	$348.90M	$0.37	181.97
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A

BioMarin Pharmaceutical has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market. Comparatively, Gemini Therapeutics has a beta of -0.12, indicating that its stock price is 112% less volatile than the broader market.

In the previous week, BioMarin Pharmaceutical had 25 more articles in the media than Gemini Therapeutics. MarketBeat recorded 25 mentions for BioMarin Pharmaceutical and 0 mentions for Gemini Therapeutics. BioMarin Pharmaceutical's average media sentiment score of 0.77 beat Gemini Therapeutics' score of 0.00 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media.

Company	Overall Sentiment
BioMarin Pharmaceutical	Positive
Gemini Therapeutics	Neutral

Summary

BioMarin Pharmaceutical beats Gemini Therapeutics on 15 of the 16 factors compared between the two stocks.

How does Gemini Therapeutics compare to Exelixis?

Gemini Therapeutics (NASDAQ:GMTX) and Exelixis (NASDAQ:EXEL) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

75.4% of Gemini Therapeutics shares are owned by institutional investors. Comparatively, 85.3% of Exelixis shares are owned by institutional investors. 12.9% of Gemini Therapeutics shares are owned by insiders. Comparatively, 2.6% of Exelixis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Exelixis has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A
Exelixis	$2.32B	5.42	$782.57M	$3.18	15.96

In the previous week, Exelixis had 19 more articles in the media than Gemini Therapeutics. MarketBeat recorded 19 mentions for Exelixis and 0 mentions for Gemini Therapeutics. Exelixis' average media sentiment score of 0.59 beat Gemini Therapeutics' score of 0.00 indicating that Exelixis is being referred to more favorably in the news media.

Company	Overall Sentiment
Gemini Therapeutics	Neutral
Exelixis	Positive

Gemini Therapeutics has a beta of -0.12, meaning that its stock price is 112% less volatile than the broader market. Comparatively, Exelixis has a beta of 0.44, meaning that its stock price is 56% less volatile than the broader market.

Exelixis has a consensus price target of $49.79, indicating a potential downside of 1.88%. Given Exelixis' stronger consensus rating and higher probable upside, analysts plainly believe Exelixis is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Exelixis	2 Sell rating(s)	10 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.32

Exelixis has a net margin of 35.33% compared to Gemini Therapeutics' net margin of 0.00%. Exelixis' return on equity of 42.17% beat Gemini Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gemini Therapeutics	N/A	-38.78%	-35.88%
Exelixis	35.33%	42.17%	31.76%

Summary

Exelixis beats Gemini Therapeutics on 15 of the 16 factors compared between the two stocks.

How does Gemini Therapeutics compare to Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Gemini Therapeutics (NASDAQ:GMTX) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

Arrowhead Pharmaceuticals has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market. Comparatively, Gemini Therapeutics has a beta of -0.12, suggesting that its stock price is 112% less volatile than the broader market.

Gemini Therapeutics has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -47.79%. Gemini Therapeutics' return on equity of -38.78% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%
Gemini Therapeutics	N/A	-38.78%	-35.88%

62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are owned by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are owned by company insiders. Comparatively, 12.9% of Gemini Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Arrowhead Pharmaceuticals has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Arrowhead Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	14.46	-$1.63M	-$2.25	N/A
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A

Arrowhead Pharmaceuticals presently has a consensus target price of $97.33, indicating a potential upside of 14.28%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Arrowhead Pharmaceuticals is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Arrowhead Pharmaceuticals had 23 more articles in the media than Gemini Therapeutics. MarketBeat recorded 23 mentions for Arrowhead Pharmaceuticals and 0 mentions for Gemini Therapeutics. Arrowhead Pharmaceuticals' average media sentiment score of 0.10 beat Gemini Therapeutics' score of 0.00 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Arrowhead Pharmaceuticals	Neutral
Gemini Therapeutics	Neutral

Summary

Arrowhead Pharmaceuticals beats Gemini Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Gemini Therapeutics compare to Madrigal Pharmaceuticals?

Gemini Therapeutics (NASDAQ:GMTX) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.

Madrigal Pharmaceuticals has a consensus target price of $689.93, indicating a potential upside of 37.43%. Given Madrigal Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Madrigal Pharmaceuticals is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78

Gemini Therapeutics has higher earnings, but lower revenue than Madrigal Pharmaceuticals. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Madrigal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A
Madrigal Pharmaceuticals	$958.40M	12.10	-$288.28M	-$12.89	N/A

In the previous week, Madrigal Pharmaceuticals had 8 more articles in the media than Gemini Therapeutics. MarketBeat recorded 8 mentions for Madrigal Pharmaceuticals and 0 mentions for Gemini Therapeutics. Madrigal Pharmaceuticals' average media sentiment score of 1.37 beat Gemini Therapeutics' score of 0.00 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Gemini Therapeutics	Neutral
Madrigal Pharmaceuticals	Positive

75.4% of Gemini Therapeutics shares are held by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 12.9% of Gemini Therapeutics shares are held by company insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Gemini Therapeutics has a beta of -0.12, indicating that its share price is 112% less volatile than the broader market. Comparatively, Madrigal Pharmaceuticals has a beta of -1.01, indicating that its share price is 201% less volatile than the broader market.

Gemini Therapeutics has a net margin of 0.00% compared to Madrigal Pharmaceuticals' net margin of -25.32%. Gemini Therapeutics' return on equity of -38.78% beat Madrigal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gemini Therapeutics	N/A	-38.78%	-35.88%
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%

Summary

Madrigal Pharmaceuticals beats Gemini Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Gemini Therapeutics compare to Summit Therapeutics?

Gemini Therapeutics (NASDAQ:GMTX) and Summit Therapeutics (NASDAQ:SMMT) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A

In the previous week, Summit Therapeutics had 9 more articles in the media than Gemini Therapeutics. MarketBeat recorded 9 mentions for Summit Therapeutics and 0 mentions for Gemini Therapeutics. Summit Therapeutics' average media sentiment score of 0.76 beat Gemini Therapeutics' score of 0.00 indicating that Summit Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Gemini Therapeutics	Neutral
Summit Therapeutics	Positive

Gemini Therapeutics has a beta of -0.12, indicating that its share price is 112% less volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.23, indicating that its share price is 223% less volatile than the broader market.

Gemini Therapeutics' return on equity of -38.78% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gemini Therapeutics	N/A	-38.78%	-35.88%
Summit Therapeutics	N/A	-168.94%	-141.92%

75.4% of Gemini Therapeutics shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 12.9% of Gemini Therapeutics shares are held by company insiders. Comparatively, 83.5% of Summit Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summit Therapeutics has a consensus price target of $24.25, indicating a potential upside of 84.18%. Given Summit Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Summit Therapeutics is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Summit Therapeutics	2 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.38

Summary

Summit Therapeutics beats Gemini Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Gemini Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GMTX vs. The Competition

Export

Metric	Gemini Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.47B	$3.69B	$6.97B	$13.06B
Dividend Yield	N/A	3.76%	2.58%	10.72%
P/E Ratio	-80.01	10.36	269.56	25.27
Price / Sales	N/A	1,288.04	596.64	100.41
Price / Cash	N/A	103.01	70.53	50.75
Price / Book	27.69	17.39	13.00	6.30
Net Income	-$71.87M	-$13.32M	$3.45B	$347.83M
7 Day Performance	3.32%	0.34%	0.57%	0.94%
1 Month Performance	5.30%	0.13%	1.22%	0.90%
1 Year Performance	30.95%	53.78%	66.67%	20.40%

Gemini Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GMTX Gemini Therapeutics	N/A	$80.01 -0.7%	N/A	+36.5%	$3.47B	N/A	N/A	30
BMRN BioMarin Pharmaceutical	4.856 of 5 stars	$70.24 +1.0%	$88.00 +25.3%	+17.5%	$13.46B	$3.22B	189.84	3,221	Analyst Downgrade
EXEL Exelixis	3.1116 of 5 stars	$50.38 -1.9%	$49.79 -1.2%	+31.5%	$12.72B	$2.32B	15.84	1,077	Analyst Upgrade Insider Trade
ARWR Arrowhead Pharmaceuticals	2.0608 of 5 stars	$87.25 -2.2%	$97.33 +11.6%	+328.2%	$12.57B	$669.50M	N/A	400
MDGL Madrigal Pharmaceuticals	4.0484 of 5 stars	$536.20 +0.2%	$689.93 +28.7%	+35.9%	$12.37B	$958.40M	N/A	90	Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GMTX) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gemini Therapeutics (GMTX) Competitors

GMTX vs. BMRN, EXEL, ARWR, MDGL, and SMMT

How does Gemini Therapeutics compare to BioMarin Pharmaceutical?

Summary

How does Gemini Therapeutics compare to Exelixis?

Summary

How does Gemini Therapeutics compare to Arrowhead Pharmaceuticals?

Summary

How does Gemini Therapeutics compare to Madrigal Pharmaceuticals?

Summary

How does Gemini Therapeutics compare to Summit Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GMTX vs. The Competition

Gemini Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gemini Therapeutics (GMTX) Competitors

GMTX vs. BMRN, EXEL, ARWR, MDGL, and SMMT

How does Gemini Therapeutics compare to BioMarin Pharmaceutical?

Do institutionals and insiders hold more shares of BMRN or GMTX?

Is BMRN or GMTX more profitable?

Do analysts prefer BMRN or GMTX?

Which has preferable valuation & earnings, BMRN or GMTX?

Which has more volatility and risk, BMRN or GMTX?

Does the media prefer BMRN or GMTX?

Summary

How does Gemini Therapeutics compare to Exelixis?

Do institutionals & insiders believe in GMTX or EXEL?

Which has better valuation and earnings, GMTX or EXEL?

Does the media favor GMTX or EXEL?

Which has more volatility and risk, GMTX or EXEL?

Do analysts recommend GMTX or EXEL?

Is GMTX or EXEL more profitable?

Summary

How does Gemini Therapeutics compare to Arrowhead Pharmaceuticals?

Which has more volatility & risk, ARWR or GMTX?

Is ARWR or GMTX more profitable?

Do institutionals and insiders believe in ARWR or GMTX?

Which has better valuation and earnings, ARWR or GMTX?

Do analysts recommend ARWR or GMTX?

Does the media prefer ARWR or GMTX?

Summary

How does Gemini Therapeutics compare to Madrigal Pharmaceuticals?

Do analysts rate GMTX or MDGL?

Which has stronger earnings & valuation, GMTX or MDGL?

Does the media favor GMTX or MDGL?

Do insiders & institutionals believe in GMTX or MDGL?

Which has more risk and volatility, GMTX or MDGL?

Is GMTX or MDGL more profitable?

Summary

How does Gemini Therapeutics compare to Summit Therapeutics?

Which has better valuation & earnings, GMTX or SMMT?

Does the media refer more to GMTX or SMMT?

Which has more volatility and risk, GMTX or SMMT?

Is GMTX or SMMT more profitable?

Do institutionals and insiders believe in GMTX or SMMT?

Do analysts rate GMTX or SMMT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GMTX vs. The Competition

Gemini Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools